Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:42:14.890Z.
Consensus retrieved: 2026-10-06T13:22:06.893Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:42:14.890Z.
Quote observation: 2026-10-06T19:40:08.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: caaf80bca5ccea9457018b34cf7693b2821ca050e30c360cba938cf84e67b366
Forward PE Ratio (N/A) = Dated Quote Price ($34.20) / Consensus Forward EPS ($-5.63)
FORWARD PE RATIO
N/A
LB Pharmaceuticals Inc Common Stock
Market Cap
$980.66M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| LB Pharmaceuticals Inc Common Stock (LBRX) | $980.66M | N/A |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $980.55M | N/A |
| MeiraGTx Holdings plc (MGTX)vs › | $977.08M | 35.17 |
| Pacira BioSciences, Inc. (PCRX)vs › | $970.71M | N/A |
| PROCEPT BioRobotics Corporation (PRCT)vs › | $991.24M | N/A |
| Vor Biopharma Inc. (VOR)vs › | $993.23M | N/A |
| Savara Inc. (SVRA)vs › | $959.06M | N/A |
| Cullinan Therapeutics, Inc. (CGEM)vs › | $1.00B | N/A |
| Aktis Oncology, Inc. (AKTS)vs › | $953.01M | N/A |
| Immatics N.V. (IMTX)vs › | $1.01B | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $34.20, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-5.63 | $-5.87 – $-5.33 | 6 | n/m |
| 2027-12-31 | $-5.14 | $-6.07 – $-3.81 | 6 | n/m |
| 2028-12-31 | $-4.25 | $-5.93 – $-3.24 | 4 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
